A patent settlement between BioMarin and Ascendis Pharma reads, at first glance, as a licensing win for BioMarin. The more interesting question is what Ascendis avoided.
BioMarin Pharmaceutical announced Sunday it had reached a binding global settlement with Ascendis Pharma resolving patent disputes over Ascendis's growth-disorder drug Yuviwel (navepegritide). Under the terms, Ascendis will pay BioMarin a royalty equal to 20 percent of net U.S. sales, retroactive to the drug's first commercial sale, and 18 percent of net sales in the European Union, Brazil, and South Korea, with the ex-U.S. royalties running through at least May 2030. The agreement resolves a U.S. International Trade Commission Section 337 investigation and litigation in four other jurisdictions. No upfront or milestone payment was disclosed.
The straightforward read is that BioMarin won. It now collects a multi-year royalty stream on a rival's commercial product, tied to underlying intellectual property from the same drug class as its own therapy Voxzogo, without spending another dollar on research or commercialization. That royalty scales automatically with Ascendis's own sales execution, a structurally attractive position for BioMarin regardless of how large Yuviwel's market ultimately becomes.
That framing skips over what Ascendis was actually facing before this settlement. The dispute included a U.S. International Trade Commission investigation, a proceeding type that exists specifically because it can result in an order barring the importation or sale of an infringing product in the United States entirely. That is general background about how Section 337 investigations work, not a confirmed claim about the specific relief BioMarin's own complaint sought, which has not been independently established. Still, set against that kind of backdrop, a settlement in which Ascendis keeps roughly four-fifths of its net U.S. sales, and secures the right to continue selling Yuviwel across every indication it is pursuing without further litigation overhang, looks considerably better than a market-exclusion outcome would have. A 20 percent royalty is a real cost. It is a much smaller one than losing access to the U.S. market altogether.
Neither company has publicly framed the deal this way, and this reading is this desk's own interpretation of the disclosed deal mechanics rather than something either company has said outright. What is genuinely unresolved is how large Yuviwel's actual sales base is today; without that figure, the royalty's dollar impact to either company cannot be sized, and any claim about which side benefits more in absolute terms would be speculation dressed up as analysis. It is also not yet confirmed whether the 20 percent U.S. royalty runs through the same May 2030 date stated for the ex-U.S. royalties, or a different end date; the settlement as summarized does not say.
What is not speculation is the shape of the trade. BioMarin converted litigation risk into a scalable revenue line with no further capital required. Ascendis converted a market-access risk into a fixed, known cost it can build a commercial plan around. Both of those are real wins. Whether the market treats this as a BioMarin story or an Ascendis story once trading resumes will likely depend less on the settlement's actual terms than on which company's coverage the market reads first.